Author

M. J. Bentham

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:clustering· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A. Macdonald· 2 shared A. Moran· 2 shared C. S. McKimmie· 2 shared R. Foster· 2 shared S. Griffin· 2 shared A. C. Kalli· 1 shared A. Kohl· 1 shared A. Melcher· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Macdonald

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Inhibitors of the Small Membrane (M) Protein Viroporin Prevent Zika Virus Infection

E. Brown, G. Swinscoe, D. Lefteri, R. Singh, A. Moran, R. Thompson, D. Maskell, H. Beaumont, M. J. Bentham, C. Donald, A. Kohl, A. Macdonald, N. Ranson, R. Foster, C. S. McKimmie, , S. C. Griffin

This study identifies the ZIKV M protein as a therapeutic target, showing that inhibitors like rimantadine block viral infection in vitro and in vivo by targeting M-formed channels.

eLife · Aug 23, 2024Peer-reviewedMicrobiology

IFNB induced by non-lytic virus immunotherapy promotes improved survival in hepatocellular carcinoma, mediated by MHCII-independent cytotoxic CD4+ T-cells

R. Hughes, A. Moran, K. J. Scott, E. Appleton, M. J. Bentham, E. Ilett, A. Melcher, A. Macdonald, A. Samson, S. Griffin

This paper shows that uv-inactivated reovirus combined with sorafenib improves survival in HCC by promoting IFNβ-induced cytotoxic CD4+ T-cell responses that are MHCII-independent.

bioRxiv · Feb 23, 2024 · PreprintImmunology

Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza

C. Scott, J. Kankanala, T. L. Foster, D. Goldhill, K. J. Simmons, M. Pingen, M. J. Bentham, E. Atkins, E.-A. Loundras, R. Elderfield, J. K. Claridge, J. Thompson, R. Stilwell, R. Tathineni, C. S. McKimmie, , S. Griffin

The paper identifies M2-N31 inhibitors that show synergistic antiviral effects when combined with existing drugs, offering a strategy to combat rimantadine-resistant influenza.

bioRxiv · Jul 24, 2019Microbiology